Canature Health(SZ:300272) Shenwan Hongyuan Securities·2025-05-05 05:43Investment Rating - The investment rating for the company is "Outperform" [1] Core Views - The company's Q1 2025 revenue performance exceeded expectations, with a revenue of 405 million yuan, representing a year-on-year growth of 6% [6] - The decline in net profit for 2024 was primarily due to one-time gains and losses, while the adjusted net profit for 2024 would show a slight increase of 2.71% year-on-year [6] - The overseas business has shown significant growth, with contributions from regions such as the Middle East (62%), Europe (16%), Asia (14%), and North America (5%) [6] - The company's gross margin improved to 39% in 2024, up by 1.47 percentage points, attributed to increased production and enhanced digital management [6] - The company has adjusted its profit forecasts for 2025 and 2026, now expecting net profits of 1.40 billion yuan and 1.70 billion yuan respectively, with a new forecast for 2027 at 1.83 billion yuan [6] Financial Data and Earnings Forecast - Total revenue for 2024 was 1,689 million yuan, with a projected revenue of 1,796 million yuan for 2025, reflecting a growth rate of 6.4% [5] - The net profit for 2024 was 84 million yuan, with an expected increase to 140 million yuan in 2025, indicating a year-on-year growth of 67.8% [5] - The earnings per share (EPS) for 2025 is projected to be 0.24 yuan, with a price-to-earnings (P/E) ratio of 24 [5]